Evidence map›Paper›PMID 34030212›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2021

Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing.

Suzanne M Jan de Beur, Paul D Miller, Thomas J Weber, Munro Peacock, Karl Insogna, Rajiv Kumar, Frank Rauch, Diana Luca, Tricia Cimms, Mary Scott Roberts and 2 more

Open access · hybridAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Suzanne M Jan de BeurJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Paul D MillerColorado Center for Bone Research, Lakewood, CO, USA.
Thomas J WeberDuke University, Durham, NC, USA.
Munro PeacockIndiana University School of Medicine, Indianapolis, IN, USA.
Karl InsognaYale University School of Medicine, New Haven, CT, USA.
Rajiv KumarMayo Clinic College of Medicine, Rochester, MN, USA.
Frank RauchMcGill University, Montreal, Canada.
Diana LucaUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Tricia CimmsUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Mary Scott RobertsUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Javier San MartinUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Thomas O CarpenterYale University School of Medicine, New Haven, CT, USA.
Ultragenyx Pharmaceutical (United States) · USYale University · USColorado Center for Bone Research · USDuke University · USIndiana University School of MedicineJohns Hopkins University · USMayo Clinic · USMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

OsteomalaciaParaneoplastic SyndromesAntibodies, Monoclonal, HumanizedHumansAntibodies, Monoclonal, Humanizedburosumab

Identifiers

PMID34030212
PMCPMC9290665
OpenAlexW3164793944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.